Neuroendocrine Neoplasm Clinical Trials

14 recruiting

Neuroendocrine Neoplasm Trials at a Glance

37 actively recruiting trials for neuroendocrine neoplasm are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 2 with 13 trials, with the heaviest enrollment activity in San Francisco, Los Angeles, and Atlanta. Lead sponsors running neuroendocrine neoplasm studies include Boehringer Ingelheim, European Institute of Oncology, and National Cancer Institute (NCI).

Browse neuroendocrine neoplasm trials by phase

Treatments under study

About Neuroendocrine Neoplasm Clinical Trials

Looking for clinical trials for Neuroendocrine Neoplasm? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neuroendocrine Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neuroendocrine Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 37 trials

Recruiting
Phase 2

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Lung Neuroendocrine NeoplasmAdvanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine Tumor+9 more
National Cancer Institute (NCI)70 enrolled29 locationsNCT04665739
Recruiting
Phase 1

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Neuroendocrine Neoplasms
Boehringer Ingelheim55 enrolled19 locationsNCT06132113
Recruiting
Phase 1

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Boehringer Ingelheim300 enrolled12 locationsNCT04429087
Recruiting
Phase 2

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Neuroendocrine TumorsParagangliomaPheochromocytoma+1 more
National Cancer Institute (NCI)130 enrolled1 locationNCT03206060
Recruiting
Phase 2

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Neuroendocrine NeoplasmsSmall Cell Lung CarcinomaExtra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim204 enrolled59 locationsNCT05882058
Recruiting
Phase 1Phase 2

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Neuroendocrine TumorsNeuroendocrine NeoplasmsGastroenteropancreatico Tumors
National Cancer Institute (NCI)56 enrolled1 locationNCT04086485
Recruiting
Phase 2

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Malignant Solid NeoplasmLung Neuroendocrine NeoplasmDigestive System Neuroendocrine Neoplasm+1 more
Roswell Park Cancer Institute60 enrolled1 locationNCT06202066
Recruiting
Phase 1Phase 2

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Neuroendocrine NeoplasmNeuroendocrine TumorsSST2-positive Neuroendocrine Neoplasms
Crinetics Pharmaceuticals Inc.150 enrolled21 locationsNCT07129252
Recruiting
Phase 3

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Neuroendocrine TumorsLung Neuroendocrine NeoplasmThymus Neoplasms
Grupo Espanol de Tumores Neuroendocrinos120 enrolled27 locationsNCT05918302
Recruiting
Phase 1

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Digestive System Neuroendocrine TumorUnresectable Digestive System Neuroendocrine NeoplasmUnresectable Digestive System Neuroendocrine Tumor G1+1 more
Emory University15 enrolled2 locationsNCT07150546
Recruiting

Project: Every Child for Younger Patients With Cancer

Malignant Solid NeoplasmNeuroendocrine NeoplasmCentral Nervous System Neoplasm+15 more
Children's Oncology Group75,000 enrolled278 locationsNCT02402244
Recruiting
Phase 1

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic or Locally Advanced Neuroendocrine Prostate Cancer+5 more
SystImmune Inc.120 enrolled20 locationsNCT07080242
Recruiting
Phase 2

Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors

Neuroendocrine TumorsNeuroendocrine Neoplasms (Tumours)Metastatic Neuroendocrine Tumors
Tata Memorial Hospital20 enrolled2 locationsNCT07404176
Recruiting

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

Pancreatic Neuroendocrine Neoplasm
University of California, San Francisco300 enrolled3 locationsNCT05746182
Recruiting

Risk Factors for Neuroendocrine Neoplasms

Neuroendocrine Neoplasm of LungNeuroendocrine Neoplasm of Gastrointestinal Tract (Disorder)
Bavarian Cancer Registry14,250 enrolled1 locationNCT06282016
Recruiting
Phase 4

Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms

Neuroendocrine TumorsNeuroendocrine Neoplasms
Shanghai Zhongshan Hospital350 enrolled4 locationsNCT07272512
Recruiting
Phase 4

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Metastatic Malignant Neoplasm in the LiverDigestive System Neuroendocrine Tumor G1Digestive System Neuroendocrine Tumor G2+3 more
Vanderbilt-Ingram Cancer Center6 enrolled1 locationNCT06016855
Recruiting
Phase 2

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

High Grade Neuroendocrine Neoplasms
Washington University School of Medicine32 enrolled2 locationsNCT06926634
Recruiting
Phase 1

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Small Cell Lung Carcinoma (SCLC)Neuroendocrine Neoplasms
Boehringer Ingelheim12 enrolled1 locationNCT05963867
Recruiting
Phase 1

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Breast CarcinomaUrothelial CarcinomaOvarian Carcinoma+31 more
Jonsson Comprehensive Cancer Center30 enrolled1 locationNCT07118176